Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial
media
posted on 2021-05-26, 15:19 authored by Adis journals on behalf of:, Luís Puig, Andrey L. Bakulev, Muza M. Kokhan, Alexey V. Samtsov, Vladislav R. Khairutdinov, Maria A. Morozova, Nikita A. Zolkin, Ivan V. Kuryshev, Alexey N. Petrov, Antonina V. Artemeva, Arina V. Zinkina-OrikhanArticle full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
